BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 2422137)

  • 1. 3-Deazauridine (NSC 126849): an interesting modulator of biochemical response.
    Moriconi WJ; Slavik M; Taylor S
    Invest New Drugs; 1986; 4(1):67-84. PubMed ID: 2422137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetics of deamination of 5-aza-2'-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside.
    Chabot GG; Bouchard J; Momparler RL
    Biochem Pharmacol; 1983 Apr; 32(7):1327-8. PubMed ID: 6189497
    [No Abstract]   [Full Text] [Related]  

  • 3. Enzyme pattern-directed chemotherapy: synergistic interaction of 3-deazauridine with D-galactosamine.
    Jackson RC; Williams JC; Weber G
    Cancer Treat Rep; 1976 Jul; 60(7):835-43. PubMed ID: 188552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The mechanism of action of 3-deazauridine in tumor cells sensitive and resistant to arabinosylcytosine.
    Brockman RW; Shaddix SC; Williams M; Nelson JA; Rose LM; Schabel FM
    Ann N Y Acad Sci; 1975 Aug; 255():501-21. PubMed ID: 171997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytidine and deoxycytidylate deaminase inhibition by uridine analogs.
    Drake JC; Hande KR; Fuller RW; Chabner BA
    Biochem Pharmacol; 1980 Mar; 29(5):807-11. PubMed ID: 20227960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxic and biochemical effects of thymidine and 3-deazauridine on human tumor cells.
    Lockshin A; Mendoza JT; Giovanella BC; Stehlin JS
    Cancer Res; 1984 Jun; 44(6):2534-9. PubMed ID: 6722792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicity of combinations of arabinosylcytosine and 3-deazauridine toward neoplastic cells in culture.
    Mills-Yamamoto C; Lauzon GJ; Paterson AR
    Biochem Pharmacol; 1978 Jan; 27(2):181-6. PubMed ID: 623673
    [No Abstract]   [Full Text] [Related]  

  • 8. Altered 5-azacytidine metabolism following 3-deazauridine treatment of L5178Y and human myeloblasts.
    Grant S; Cadman E
    Cancer Res; 1980 Nov; 40(11):4000-6. PubMed ID: 6162541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine.
    Li ZR; Campbell J; Rustum YM
    Cancer Treat Rep; 1983 Jun; 67(6):547-54. PubMed ID: 6190558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of anti-neoplastic activity of cytosine arabinoside against human HL-60 myeloid leukemic cells by 3-deazauridine.
    Momparler RL; Bouffard DY; Momparler LF; Marquet J; Zittoun J; Marie JP; Zittoun R
    Int J Cancer; 1991 Oct; 49(4):573-6. PubMed ID: 1917159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Labelling of the thymidine and deoxycytidine bases of DNA by [2-14C]deoxycytidine in cultured L1210 cells.
    Karle JM; Hoerauf RM; Cysyk RL
    Cancer Lett; 1983 Jun; 19(2):147-57. PubMed ID: 6883305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic action of 5-aza-2'-deoxycytidine and 3-deazauridine on L1210 leukemic cells and EMT6 tumor cells.
    Momparler RL; VeselĂ˝ J; Momparler LF; Rivard GE
    Cancer Res; 1979 Oct; 39(10):3822-7. PubMed ID: 476619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme pattern-directed chemotherapy. Effects of antipyrimidine combinations on the ribonucleotide content of hepatomas.
    Lui MS; Jackson RC; Weber G
    Biochem Pharmacol; 1979 Apr; 28(7):1189-95. PubMed ID: 444276
    [No Abstract]   [Full Text] [Related]  

  • 14. Transport of uridine and 3-deazauridine in cultured human lymphoblastoid cells.
    Dahlig-Harley E; Paterson AR; Robins MJ; Cass CE
    Cancer Res; 1984 Jan; 44(1):161-5. PubMed ID: 6580947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3-Deazauridine enhances the antileukemic action of 5-aza-2'-deoxycytidine and targets drug-resistance due to deficiency in deoxycytidine kinase.
    Raynal NJ; Momparler LF; Rivard GE; Momparler RL
    Leuk Res; 2011 Jan; 35(1):110-8. PubMed ID: 20510451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous determination of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and 3-deazauridine 5'-triphosphate in human leukemia cells by high-performance liquid chromatography.
    Plunkett W; Chubb S; Barlogie B
    J Chromatogr; 1980 Dec; 221(2):425-30. PubMed ID: 6938519
    [No Abstract]   [Full Text] [Related]  

  • 17. Regulation of pyrimidine biosynthesis in cultured L1210 cells by 3-deazauridine.
    Karle JM; Cysyk RL
    Biochem Pharmacol; 1984 Dec; 33(23):3739-42. PubMed ID: 6095859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytidine 5'-triphosphate synthetase as a target for inhibition by the antitumor agent 3-deazauridine.
    McPartland RP; Wang MC; Bloch A; Weinfeld H
    Cancer Res; 1974 Nov; 34(11):3107-11. PubMed ID: 4472653
    [No Abstract]   [Full Text] [Related]  

  • 19. Cell cycle arrest as a basis of enhancement of 1-beta-D-arabinofuranosylcytosine anabolism in human lymphoblastoid RPMI 6410 cells cultured with 3-deazauridine.
    Lauzon GJ; Yang S; Paterson AR
    Biochem Pharmacol; 1981 Jul; 30(14):1889-94. PubMed ID: 6895033
    [No Abstract]   [Full Text] [Related]  

  • 20. In vivo cellular kinetic and pharmacological studies of 1-beta-D-arabinofuranosylcytosine and 3-deazauridine chemotherapy for relapsing acute leukemia.
    Barlogie B; Plunkett W; Raber M; Latreille J; Keating M; McCredie K
    Cancer Res; 1981 Mar; 41(3):1227-35. PubMed ID: 7459863
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.